Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Ptc Therapeutics (PTCT)

Ptc Therapeutics (PTCT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,526,615
  • Shares Outstanding, K 62,633
  • Annual Sales, $ 306,980 K
  • Annual Income, $ -251,580 K
  • 60-Month Beta 1.59
  • Price/Sales 8.86
  • Price/Cash Flow N/A
  • Price/Book 4.50

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -1.00
  • Number of Estimates 3
  • High Estimate -0.69
  • Low Estimate -1.19
  • Prior Year -0.91
  • Growth Rate Est. (year over year) -9.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
30.79 +38.15%
on 03/17/20
57.06 -25.45%
on 03/05/20
-12.30 (-22.43%)
since 02/28/20
3-Month
30.79 +38.15%
on 03/17/20
59.89 -28.97%
on 02/19/20
-6.27 (-12.85%)
since 12/27/19
52-Week
30.79 +38.15%
on 03/17/20
59.89 -28.97%
on 02/19/20
+4.90 (+13.02%)
since 03/29/19

Most Recent Stories

More News
PTC Therapeutics Announces Management Change

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Marcio Souza, Chief Operating Officer, has resigned and will be leaving the company by April 25th, 2020.

PTCT : 42.54 (+5.45%)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on March 6, 2020 it approved non-statutory stock options to purchase an aggregate of 103,750 shares of its common stock to 35 new employees. The...

PTCT : 42.54 (+5.45%)
PTC Therapeutics (PTCT) Reports Q4 Loss, Tops Revenue Estimates

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -116.98% and 8.68%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

PTCT : 42.54 (+5.45%)
PTC Therapeutics: 4Q Earnings Snapshot

SOUTH PLAINFIELD, N.J. (AP) _ PTC Therapeutics Inc. (PTCT) on Monday reported a loss of $77.7 million in its fourth quarter.

PTCT : 42.54 (+5.45%)
PTC Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides a Corporate Update

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the fourth quarter and full year ending December 31, 2019.

PTCT : 42.54 (+5.45%)
PTC Therapeutics to Participate at Upcoming Investor Conferences

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present at the following conferences:

PTCT : 42.54 (+5.45%)
Analysts Estimate PTC Therapeutics (PTCT) to Report a Decline in Earnings: What to Look Out for

PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PTCT : 42.54 (+5.45%)
Ptc Therapeutics Falls 5.06% on Heavy Volume: Watch For Potential Rebound

Ptc Therapeutics (NASDAQ:PTCT) traded in a range yesterday that spanned from a low of $56.22 to a high of $58.14. Yesterday, the shares fell 5.1%, which took the trading range below the 3-day low of...

PTCT : 42.54 (+5.45%)
Shares of PTCT Up 53.9% Since Uptrend Call on Shares

SmarTrend identified an Uptrend for Ptc Therapeutics (NASDAQ:PTCT) on October 23rd, 2019 at $37.80. In approximately 4 months, Ptc Therapeutics has returned 53.88% as of today's recent price of $58.16....

PTCT : 42.54 (+5.45%)
PTC Therapeutics Launches Sixth Annual STRIVE Awards Program for Advocacy Organizations in Duchenne Muscular Dystrophy

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the sixth annual STRIVE grant awards program for Duchenne muscular dystrophy. The STRIVE Awards provide a grant to patient advocacy organizations...

PTCT : 42.54 (+5.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade PTCT with:

Business Summary

PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States.

See More

Key Turning Points

2nd Resistance Point 44.49
1st Resistance Point 43.51
Last Price 42.54
1st Support Level 40.95
2nd Support Level 39.37

See More

52-Week High 59.89
Fibonacci 61.8% 48.77
Fibonacci 50% 45.34
Last Price 42.54
Fibonacci 38.2% 41.91
52-Week Low 30.79

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar